Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nextcure Inc.

5.03
-0.1000-1.95%
Post-market: 5.030.00000.00%17:55 EDT
Volume:5.87K
Turnover:29.81K
Market Cap:13.46M
PE:-0.24
High:5.18
Open:5.10
Low:5.02
Close:5.13
52wk High:19.20
52wk Low:2.69
Shares:2.68M
Float Shares:2.06M
Volume Ratio:0.47
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-21.2313
EPS(LYR):-23.8819
ROE:-105.88%
ROA:-53.12%
PB:0.45
PE(LYR):-0.21

Loading ...

NextCure Inc. Announces Resignation of Chief Scientific Officer Solomon Langermann, Effective September 1, 2025

Reuters
·
Aug 26

NextCure Inc. Files Initial Statement of Beneficial Ownership for Simcere Zaiming, Inc

Reuters
·
Aug 20

NextCure Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

NextCure (NXTC) Q2 Loss Widens 71%

Motley Fool
·
Aug 08

NextCure Q2 EPS $(11.29) Misses $(0.39) Estimate

Benzinga
·
Aug 08

NextCure Inc. Unveils Corporate Presentation Highlighting Licensing Agreement with Simcere and Progress in ADC Clinical Trials

Reuters
·
Aug 08

NextCure Inc expected to post a loss of $4.61 a share - Earnings Preview

Reuters
·
Jul 28

NextCure Shares Surge on Positive Data for Bone Treatment

Dow Jones
·
Jul 26

NextCure presents new preclinical data on osteogenesis imperfecta treatment

TIPRANKS
·
Jul 25

NextCure Inc. Announces Promising Preclinical Results for Anti-Siglec-15 Treatment NC605 in Osteogenesis Imperfecta Model

Reuters
·
Jul 25

U.S. RESEARCH ROUNDUP-Nvidia, Strategy, Targa Resources

Reuters
·
Jul 15

NextCure Inc. Announces 1:12 Reverse Stock Split in Bylaw Amendment

Reuters
·
Jul 14

NextCure trading halted, news pending

TIPRANKS
·
Jul 12

NextCure Inc. Announces 1-for-12 Reverse Stock Split Effective July 14, 2025

Reuters
·
Jul 10

Ladenburg Thalmann & Co. Reaffirms Their Hold Rating on NextCure (NXTC)

TIPRANKS
·
Jul 08

NextCure Inc. Unveils Presentation on Licensing Agreement with Simcere Zaiming and Development Plans for Novel Therapeutic Candidates

Reuters
·
Jul 07

NextCure Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 01

NextCure Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 23

BRIEF-Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure

Reuters
·
Jun 16

NextCure Inc. Unveils Corporate Presentation Highlighting Licensing Agreement and Clinical Trial Developments

Reuters
·
Jun 16